Multidisciplinary management and radiotherapy recommendations for clinically and pathologically node-positive bladder cancer
Liauw, S. L.
Baumann, B. C.
Efstathiou, J. A.
Solanki, A. A.
AffiliationDepartment of Radiation Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Stritch School of Medicine, Maywood,
MetadataShow full item record
AbstractThere are limited data regarding the optimal management of patients with pelvic node-positive, but non-metastatic, bladder cancer. Increasing data demonstrate that this is a distinct clinical entity with outcomes bridging between bladder-confined muscle-invasive bladder cancer and metastatic advanced bladder cancer. Guidelines and staging systems have formalized the need to incorporate the unique considerations of management of pelvic node-positive bladder cancer. However, there remains an absence of a definite standard of care. Treatment options include systemic therapy alone, neoadjuvant chemotherapy followed by radical cystectomy, or bladder-preserving trimodality therapy. Furthermore, ongoing studies aim to determine the benefit of incorporating immunotherapy into these treatment paradigms. In this review article, we will discuss the key considerations for management of patients with pelvic node-positive bladder cancer.
CitationVenkatesulu B, Liauw SL, Joshi M, Baumann BC, Yoo R, Roupret M, et al. Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer. Seminars in radiation oncology. 2023 Jan;33(1):35-50. PubMed PMID: 36517192. Epub 2022/12/15. eng.
JournalSeminars in Radiation Oncology